search
Back to results

Efficacy of Probiotics for NSAID-induced Enteropathy in Arthritis Patients (NSAID)

Primary Purpose

Osteoarthritis

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Probiotics capsule
Placebo capsule
Sponsored by
Jae Myung Park
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Osteoarthritis

Eligibility Criteria

19 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with axial SpA who meet the 2009 ASAS criteria or osteoarthritis diagnosed by hand or foot x-rays Exclusion Criteria: History of taking NSAIDs or antibiotics within the last month Those who have been taking probiotics, steroids, or immunosuppressants for a long time Abdominal surgical history (exception: appendectomy, cholecystectomy) History of gastrointestinal malignant disease Abnormal findings requiring drug treatment or surgery in upper gastrointestinal endoscopy (e.g., digestive cancer, acute peptic ulcer, etc.) Hemorrhagic disease Anemia with hemoglobin less than 10 g/dL Past NSAIDs drug side effects (allergy)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Probiotics arm

    Placebo arm

    Arm Description

    Probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) per oral, three times a day, for 8 weeks

    Placebo capsule in the same form as probiotics, per oral, three times a day, for 8 weeks

    Outcomes

    Primary Outcome Measures

    Changes in the small bowel injuries on capsule endoscopy
    Changes in the number of ulcers/erosions in the small bowel mucosa on capsule endoscopy before and after taking the NSAIDs and Probiotics/Placebo

    Secondary Outcome Measures

    Change from Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Questionnaire Scores
    Change from Baseline in Gastrointestinal Symptom Rating Scale Questionnaire Scores at 8 Weeks Symptoms: Pain or discomfort in upper abdomen, Heartburn, Acid reflux, Hunger pangs, Nausea, Rumbling, Bloating, Passing gas, Constipation, Diarrhea, Loose stool, Hard stool, Urgent bowel movement, Sensation of not completely emptying bowel Scoring: Each of the 15 items is scored from 0 to 6 points, with the highest score being 45 points and the lowest being 0 points. A score of 0 means no gastrointestinal symptoms, and a higher score indicates a more frequent occurrence of the corresponding symptoms.
    Change From Baseline in Symptom Scores on the Western Ontario and McMaster Universities (WOMAC) Arthritis Index
    WOMAC index: Descending stairs, Ascending stairs, Rising from sitting, Standing, Bending to floor, Walking on flat surface, Getting in/out of car, Going shopping, Putting on socks, Lying in bed, Talking off socks, Rising from bed, Getting in/out of bath, Sitting, Getting on/off toilet, Heavy domestic duties, Light domestic duties Each of the 24 items is scored from 0 to 4 points, with the highest score being 96 points and the lowest being 0 points. A score of 0 means no symptoms and a higher score indicates more severe symptoms of the corresponding symptoms.
    Change From Baseline in Symptom Scores on the Knee Injury and Osteoarthritis Outcome Scores (KOOS) Questionnaire at 8 Weeks
    Assessment of KOOS: Daily living, Sports and recreational activities, Pain, Quality of life, Symptoms and stiffness Each of the 42 items is scored from 0 to 4 points, with the highest score being 168 points and the lowest being 0 points. A score of 0 means no symptoms, and a higher score indicates more severe and frequent symptoms of the corresponding symptoms.
    Changes in the gut microbiome through Next Generation Sequencing
    Changes in composition and diversity of gut microbiota through stool samples Changes in microbial genome composition

    Full Information

    First Posted
    July 20, 2023
    Last Updated
    August 11, 2023
    Sponsor
    Jae Myung Park
    Collaborators
    Daewoong Pharmaceutical Co. LTD.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05993247
    Brief Title
    Efficacy of Probiotics for NSAID-induced Enteropathy in Arthritis Patients
    Acronym
    NSAID
    Official Title
    Efficacy of Probiotics for Non-steroidal Anti-inflammatory Drug-induced Enteropathy in Arthritis Patients: A Double-blinded Pilot Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    August 20, 2023 (Anticipated)
    Primary Completion Date
    August 31, 2025 (Anticipated)
    Study Completion Date
    August 31, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Jae Myung Park
    Collaborators
    Daewoong Pharmaceutical Co. LTD.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This study aimed to investigate the efficacy of probiotics as a preventive agent for NSAID-induced enteropathy. Arthritis patients are randomly divided into probiotic and placebo groups, and the drug is administered for eight weeks. Before and after drug administration, the patient's symptoms/degree of small bowel injuries on capsule endoscopy/microbiome composition and diversity were investigated.
    Detailed Description
    Background: Due to aging, there are many long-term users of NSAIDs, increasing enteropathy. The prophylactic effect of misoprostol, which is currently used, has not been proven, and misoprostol's long-term compliance and safety remain questionable. Rebamipide shows insignificant effects in both treatment and prophylaxis. Probiotics have been reported to affect enteropathy in animal and human studies. However, there needs to be more verification studies, and there needs to be confirmatory studies on the importance of the microbiome in the small bowel. However, it is expected that there will be fewer complications and less patient resistance, resulting in higher drug compliance. Purpose: To identify the efficacy of probiotics on NSAID-induced enteropathy in arthritis patients by capsule endoscopy and questionnaire, and to analysis the composition and diversity of the microbiome Design: Double-blinded randomized controlled, pilot study Participant: Patients diagnosed with osteoarthritis and starting NSAIDs Methods: Randomly administering Probiotics or Placebo for eight weeks and comparing "before and after administration" in arthritis patients Survey of patient symptoms for enteropathy Recovery of small bowel mucosal injuries in capsule endoscopy Analysis of the composition and diversity of the microbiome Adverse events Outcome Primary outcome: To assess whether probiotics can reduce small bowel injuries caused by NSAIDs Secondary outcome: To investigate whether probiotics can reduce gastrointestinal symptoms caused by NSAIDs To identify the improvement of arthritis symptoms To examine whether the distribution of the microbiome can be converted into beneficial bacteria by administering probiotics

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Osteoarthritis

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Model Description
    Probiotics group vs. Placebo group
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    36 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Probiotics arm
    Arm Type
    Active Comparator
    Arm Description
    Probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) per oral, three times a day, for 8 weeks
    Arm Title
    Placebo arm
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo capsule in the same form as probiotics, per oral, three times a day, for 8 weeks
    Intervention Type
    Combination Product
    Intervention Name(s)
    Probiotics capsule
    Intervention Description
    Subjects will take a probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) three times a day for 8 weeks in combination with NSAIDs
    Intervention Type
    Combination Product
    Intervention Name(s)
    Placebo capsule
    Intervention Description
    Subjects will take a placebo capsule identical in shape and size to probiotics capsule three times a day for 8 weeks in combination with NSAIDs
    Primary Outcome Measure Information:
    Title
    Changes in the small bowel injuries on capsule endoscopy
    Description
    Changes in the number of ulcers/erosions in the small bowel mucosa on capsule endoscopy before and after taking the NSAIDs and Probiotics/Placebo
    Time Frame
    From enrollment to the end of treatment at 8 weeks
    Secondary Outcome Measure Information:
    Title
    Change from Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Questionnaire Scores
    Description
    Change from Baseline in Gastrointestinal Symptom Rating Scale Questionnaire Scores at 8 Weeks Symptoms: Pain or discomfort in upper abdomen, Heartburn, Acid reflux, Hunger pangs, Nausea, Rumbling, Bloating, Passing gas, Constipation, Diarrhea, Loose stool, Hard stool, Urgent bowel movement, Sensation of not completely emptying bowel Scoring: Each of the 15 items is scored from 0 to 6 points, with the highest score being 45 points and the lowest being 0 points. A score of 0 means no gastrointestinal symptoms, and a higher score indicates a more frequent occurrence of the corresponding symptoms.
    Time Frame
    From enrollment to the end of treatment at 8 weeks
    Title
    Change From Baseline in Symptom Scores on the Western Ontario and McMaster Universities (WOMAC) Arthritis Index
    Description
    WOMAC index: Descending stairs, Ascending stairs, Rising from sitting, Standing, Bending to floor, Walking on flat surface, Getting in/out of car, Going shopping, Putting on socks, Lying in bed, Talking off socks, Rising from bed, Getting in/out of bath, Sitting, Getting on/off toilet, Heavy domestic duties, Light domestic duties Each of the 24 items is scored from 0 to 4 points, with the highest score being 96 points and the lowest being 0 points. A score of 0 means no symptoms and a higher score indicates more severe symptoms of the corresponding symptoms.
    Time Frame
    From enrollment to the end of treatment at 8 weeks
    Title
    Change From Baseline in Symptom Scores on the Knee Injury and Osteoarthritis Outcome Scores (KOOS) Questionnaire at 8 Weeks
    Description
    Assessment of KOOS: Daily living, Sports and recreational activities, Pain, Quality of life, Symptoms and stiffness Each of the 42 items is scored from 0 to 4 points, with the highest score being 168 points and the lowest being 0 points. A score of 0 means no symptoms, and a higher score indicates more severe and frequent symptoms of the corresponding symptoms.
    Time Frame
    From enrollment to the end of treatment at 8 weeks
    Title
    Changes in the gut microbiome through Next Generation Sequencing
    Description
    Changes in composition and diversity of gut microbiota through stool samples Changes in microbial genome composition
    Time Frame
    From enrollment to the end of treatment at 8 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    19 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients with axial SpA who meet the 2009 ASAS criteria or osteoarthritis diagnosed by hand or foot x-rays Exclusion Criteria: History of taking NSAIDs or antibiotics within the last month Those who have been taking probiotics, steroids, or immunosuppressants for a long time Abdominal surgical history (exception: appendectomy, cholecystectomy) History of gastrointestinal malignant disease Abnormal findings requiring drug treatment or surgery in upper gastrointestinal endoscopy (e.g., digestive cancer, acute peptic ulcer, etc.) Hemorrhagic disease Anemia with hemoglobin less than 10 g/dL Past NSAIDs drug side effects (allergy)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jae Myung Park, MD
    Phone
    +82222586023
    Email
    parkjerry@catholic.ac.kr
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jae Myung Park, MD
    Organizational Affiliation
    The Catholic University of Korea
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    Efficacy of Probiotics for NSAID-induced Enteropathy in Arthritis Patients

    We'll reach out to this number within 24 hrs